{"doi":"10.17615/srnw-7r35","title":"δ-Catenin, a Wnt/β-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming","abstract":"Mutations of Wnt/β-catenin signaling pathway play essential roles in development and cancer. Although β-catenin and adenomatous polyposis coli (APC) gene mutations are well established and are known to drive tumorigenesis, discoveries of mutations in other components of the pathway lagged which hinders the understanding of cancer mechanisms. Here we report that δ-catenin (gene designation: CTNND2), a primarily neural member of the β-catenin superfamily which promotes canonical Wnt/β-catenin/LEF-1-mediated transcription, displays exonic mutations in human prostate cancer and promotes cancer cell survival adaptation and metabolic reprogramming. When overexpressed in cells derived from prostate tumor xenografts, δ-catenin gene invariably gave rise to mutations leading to sequence disruptions predicting functional alterations. Ectopic δ-catenin gene integrating into host chromosomes is locus non-selective. δ-Catenin mutations promote tumor development in mouse prostate with probasin promoter (ARR2PB)-driven, prostate-specific expression of myc oncogene, while mutant cells empower survival advantage upon overgrowth and glucose deprivation. Reprogramming energy utilization accompanies the down-regulation of glucose transporter-1 (Glut-1) and Poly (ADP-ribose) polymerase (PARP) cleavage while preserving tumor type 2 pyruvate kinase (PKM2) expression. δ-Catenin mutations increased β-catenin translocation to the nucleus and HIF-1α expression. Therefore, introducing δ-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating β-catenin and HIF-1α signaling under glucose shortage to amplify its tumor promoting potential.","journal":"UNC Libraries","year":2020,"id":139240,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9534,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":602563,"name":"C. Boykin","orcid":null,"position":1,"is_corresponding":false},{"id":602564,"name":"H. Hong","orcid":null,"position":2,"is_corresponding":false},{"id":602565,"name":"J. Nopparat","orcid":null,"position":3,"is_corresponding":false},{"id":602029,"name":"Jianping Lu","orcid":"0000-0001-9601-0040","position":4,"is_corresponding":false},{"id":602566,"name":"P. D. Neufer","orcid":null,"position":5,"is_corresponding":false},{"id":602030,"name":"Qian Lu","orcid":"0009-0002-9663-3525","position":6,"is_corresponding":false},{"id":602031,"name":"Yuli Chen","orcid":"0000-0001-7095-6479","position":7,"is_corresponding":false},{"id":602032,"name":"Jinyu Fan","orcid":"0009-0004-5648-6203","position":8,"is_corresponding":false},{"id":10783,"name":"J. Zhang","orcid":"0000-0002-4380-1655","position":9,"is_corresponding":false},{"id":602562,"name":"D. Zheng","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:17:10.185988Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}